3SOF

Looking at the 2 year chart,
a breakout of the Symmetrical Triangle pattern.
Support @ $14.80

News Link

http://finance.yahoo.com/q/h?s=KERX

This one has been moving for the last 3 trading days,
forgot to do an update on it.
RSI is about to move through 70

Technicals
Record Price High
13-day EMA Cross Above 50-day EMA
Close Above the 50-day EMA
Record Price Break Out
Percentage Gainer

Last Price Quote is:
11.69%above 13-day EMA
12.27%above 50-day EMA
RS Rating: 92 

Fundamentals
Key Data:
Market Cap (M): $590.27 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/07/2005
Last Analyst Rating: Overweight

AP
Keryx Trial Shows Positive Results
Thursday June 29, 11:27 am ET 
Keryx Kidney Disease Treatment Shows Promising Results in Phase 2 Trial


NEW YORK (AP) -- Biotech company Keryx Biopharmaceuticals Inc. said Thursday its mid-stage trial of a kidney disease treatment showed positive results.
The company said the drug, Zerenex, was well tolerated, safe and effective in people with end-stage kidney disease at the optimum dose of 6 grams per day.

The patients were undergoing hemodialysis. None of the more than 100 patients in the 28-day study died or had serious adverse effects that could be definitely linked to Zerenex, the company said.

Keryx rose 36 cents, or 3 percent, to $13 in midday trading on the Nasdaq. In the past 52 weeks, the stock has traded between $12.27 and $19.35.

Keryx kidney drug shows promise in mid-stage trial

BOSTON, June 29 (Reuters) - Keryx Biopharmaceuticals Inc. (KERX.O: Quote, Profile, Research) said on Thursday that its experimental drug to treat end-stage kidney disease showed promise in a mid-stage clinical trial.

The company said the drug, Zerenex, had an acceptable safety profile, with no serious adverse events that investigators determined were definitely related to the drug.

Eyes on KERX

Volume: 1,083,018
Avg Vol (3m): 358,642

Technicals
Close Above the 13-day EMA

Last Price Quote is:
4.72%above 13-day EMA
-6.04%below 50-day EMA
RS Rating: 8 

Fundamentals
Key Data:
Market Cap (M): $555.29 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2006
Last Analyst Rating: Buy

AP
Ahead of the Bell: Keryx Biopharm
Thursday August 17, 9:29 am ET 
Analyst Recommends Keryx Biopharmaceuticals, Expects Gains From Drug Sulonex


NEW YORK (AP) -- A Jefferies & Co. analyst recommended development-stage biotech company Keryx Biopharmaceuticals Inc. on Thursday, saying that the stock's price makes it a good buying opportunity.


Shares of Keryx are down 25 percent since the beginning of the year, but have increased 18 percent since hitting a year low of $9.53 on Monday.

Analyst Adam Walsh rebuffed investor concerns of competition and delays facing Sulonex, Keryx's diabetic kidney disease treatment candidate.

"We believe any perceived delay in Sulonex timelines is more a function of overly aggressive prior Street expectations rather than missed milestones," Walsh said.

Walsh reiterated a "Buy" rating on the shares with a $25 price target, applauding the company's "beefed up" management team and expecting Keryx to gain from Sulonex sales.

Walsh forecasts $36 million in Sulonex revenue in fiscal 2008, and sales to ramp up to $256 million in fiscal 2009.

Walsh noted that Sulonex is protected under a patent expiring in 2014, which Keryx said has an extension through at least 2017.

Walsh also expects Keryx to gain from hiring Ronald C. Renaud, Jr. as chief financial officer, who previously worked for JP Morgan Securities as a senior biotechnology research analyst.

Back above the 50-day MA with 3 white soldiers

Volume: 1,200,942
Avg Vol (3m): 456,654

52wk Range: 9.53 - 19.35

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
15.35%above 13-day EMA
1.40%above 50-day EMA
RS Rating: 12 

Fundamentals
Key Data:
Market Cap (M): $422.50 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Buy

Hi setravis...Great find

I believe KERX is ready for a new downtrend...

Technical analysis :
1. Chart pattern :  Symmetrical Continuation Triangle (Bearish) 
2. Trend : DOWNTREND..the end of the pullback.
3. Volume : Low on the last minor uptrend
4. Candlestick : a doji is appeared at the end of pullback.

Close at 13.00
target at 10.00
Stop loss at 14.44

JMHO....I think this uptrend is going to continue.
In my view looks like we have a Head and Shoulders Bottom ,formed.

52wk Range: 9.53 - 19.35

Volume: 473,753
Avg Vol (3m): 423,918

Technicals
Last Price Quote is:
2.28%above 13-day EMA
5.44%above 50-day EMA
RS Rating: 60 

Fundamentals
Key Data:
Market Cap (M): $561.39 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Buy

No time for comments.......
Will leave the end of the day chart

Yesterday's news.......


NEW YORK, Oct 04, 2006 /PRNewswire-FirstCall via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (KERX, Trade) today announced that it has entered into an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko), of Tokyo, Japan, for the worldwide development and commercialization rights, excluding Japan, to UCN-01 (7-hydroxystaurosporine). UCN-01 is a novel multi-kinase inhibitor for the treatment of cancer which, in preclinical models, has demonstrated a synergistic effect with agents inhibiting the PI3K pathway, including perifosine. UCN-01 is currently in several Phase II clinical trials both as a single agent and in combination with other anticancer agents which are being conducted under the direction and sponsorship of the National Cancer Institute. In accordance with the terms of the agreement, Keryx will make up-front and milestone payments as well as pay royalties on product sales.

Commenting on the in-licensing of UCN-01, I. Craig Henderson, MD, the Company's President, stated "We are excited about this drug because it targets some of the most interesting pathways involved in the propagation and survival of cancer cells and complements our ongoing program with KRX-0401 (perifosine)."

ABOUT UCN-01

UCN-01 is an anticancer drug that belongs to the family of drugs called staurosporine analogs which have demonstrated an ability to inhibit multiple kinases involved in cell-cycle progression and apoptosis, including Chk-1 and PDK1. In pre-clinical studies, UCN-01 has demonstrated synergistic effect with DNA-damaging agents including chemotherapy and radiation therapy. In-vitro, UCN-01 has been shown to be synergistic with agents affecting the PI3-K pathway including perifosine and mTOR inhibitors. In clinical trials, as reported by investigators at the National Cancer Institute, durable single-agent responses have been seen in patients with anaplastic large-cell lymphoma.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 (perifosine) is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.


 
    Contact: 
             Ronald C. Renaud, Jr.                 Thomas Redington 
             Chief Financial Officer               203 222-7399 
             212 531-5965                          212 926-1733 
             [email protected]                     [email protected] 
SOURCE   Keryx Biopharmaceuticals, Inc. 

Ronald C. Renaud, Jr., Keryx Biopharmaceuticals, Inc. +1-212-531-5965, 
[email protected]; Thomas Redington, +1-203-222-7399, +1-212-926-1733, 
[email protected] 

http://www.prnewswire.com 

Copyright (C) 2006 PR Newswire. All rights reserved ********************************************************************** As of Saturday, 09-30-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 09-26-2006 for KERX @ $12.50. For more information on Comtex SmarTrend? Alert, contact your market data provider or go to CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2006 Comtex News Network, Inc. All rights reserved.

Good here..  macd about to cross center,
look for strong volume pushing this through $17 to $19

Technicals
Close Above the 50-day MA
Close Above the 13-day MA

Last Price Quote is:
7.12%above 13-day MA
6.00%above 50-day MA
RS Rating: 18 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Buy

52wk Range: 9.53 - 19.35

Volume: 597,388
Avg Vol (3m): 409,460

Support @ $12.61...11.65...9.60
Resistance @ $13.88...14.81...17.70

 
uptrend wants to continue...

Has also formed a Symmetrical Triangle (continuation) Pattern.
JMHO, I do think a nice move is coming.
Closing in on the 200-day MA

52wk Range: 9.53 - 19.35

Volume: 368,744
Avg Vol (3m): 421,622

Technicals
Last Price Quote is:
7.24%above 13-day EMA
9.32%above 50-day EMA
RS Rating: 78 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Buy